Travis Alvin Thompson Sells 2,686 Shares of Bicycle Therapeutics plc (NASDAQ:BCYC) Stock

Bicycle Therapeutics plc (NASDAQ:BCYC) CAO Travis Alvin Thompson sold 2,686 shares of the business’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $15.00, for a total value of $40,290.00. Following the completion of the sale, the chief accounting officer now directly owns 32,146 shares of the company’s stock, valued at approximately $482,190. This represents a 7.71 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Travis Alvin Thompson also recently made the following trade(s):

• On Thursday, January 2nd, Travis Alvin Thompson sold 1,750 shares of Bicycle Therapeutics stock. The stock was sold at an average price of $14.09, for a total value of $24,657.50.
• On Monday, November 11th, Travis Alvin Thompson sold 6,256 shares of Bicycle Therapeutics stock. The shares were sold at an average price of $25.11, for a total value of $157,088.16.

Bicycle Therapeutics Stock Performance

Shares of BCYC stock traded down $0.01 during mid-day trading on Monday, hitting $14.88. 289,310 shares of the stock traded hands, compared to its average volume of 435,603. Bicycle Therapeutics plc has a twelve month low of $12.17 and a twelve month high of $28.67. The company’s 50-day simple moving average is $19.27 and its 200-day simple moving average is $21.86. The firm has a market cap of $1.03 billion, a price-to-earnings ratio of -4.52 and a beta of 0.92.

Bicycle Therapeutics (NASDAQ:BCYC) last released its earnings results on Thursday, October 31st. The company reported ($0.74) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.04. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The firm had revenue of $2.68 million for the quarter, compared to analyst estimates of $6.82 million. During the same period in the previous year, the company earned ($1.26) earnings per share. Bicycle Therapeutics’s revenue was down 50.0% compared to the same quarter last year. Analysts forecast that Bicycle Therapeutics plc will post -3.05 earnings per share for the current year.

Hedge Funds Weigh In On Bicycle Therapeutics

Several hedge funds have recently made changes to their positions in the business. Natixis Advisors LLC bought a new stake in Bicycle Therapeutics during the second quarter worth approximately $261,000. TD Asset Management Inc boosted its stake in shares of Bicycle Therapeutics by 76.7% during the 2nd quarter. TD Asset Management Inc now owns 97,186 shares of the company’s stock worth $1,967,000 after acquiring an additional 42,200 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Bicycle Therapeutics by 97.2% in the 2nd quarter. Renaissance Technologies LLC now owns 326,800 shares of the company’s stock worth $6,614,000 after acquiring an additional 161,100 shares during the last quarter. L & S Advisors Inc raised its position in shares of Bicycle Therapeutics by 16.1% during the second quarter. L & S Advisors Inc now owns 58,335 shares of the company’s stock worth $1,181,000 after purchasing an additional 8,075 shares during the period. Finally, XTX Topco Ltd acquired a new stake in shares of Bicycle Therapeutics during the second quarter worth $206,000. Institutional investors and hedge funds own 86.15% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. HC Wainwright reduced their price target on shares of Bicycle Therapeutics from $55.00 to $33.00 and set a “buy” rating on the stock in a research report on Monday, December 16th. Stephens started coverage on Bicycle Therapeutics in a research report on Friday, November 8th. They set an “equal weight” rating and a $25.00 price target on the stock. JMP Securities reduced their price objective on Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating for the company in a research report on Wednesday, December 18th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $35.00 target price on shares of Bicycle Therapeutics in a research report on Friday, November 1st. Finally, Needham & Company LLC reissued a “buy” rating and set a $38.00 price target on shares of Bicycle Therapeutics in a report on Thursday, October 31st. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $35.25.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.